Quick Answer
X4 Pharmaceuticals, Inc reported Revenue From Contract With Customer Excluding Assessed Tax of $35.11 million for the year ending 2025.
- X4 Pharmaceuticals, Inc showed an increase of +1,273.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $35.11 million | Fiscal year 2024: $2.56 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $0.00 | Fiscal year 2021: $0.00 | Fiscal year 2020: $3.00 million | Fiscal year 2019: $0.00 | Fiscal year 2018: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: